Dactinomycin
Dactinomicina
Risk class
- Vesicant
If it extravasates
Compress
- Cold
References
Risk class: VesicantONS/ASCO 2025 (Table 1, p. 385); ESMO-EONS 2012 (Table 1, p. vii167); JSCN/JSMO/JASPO 2024 (Table 2)
Compress: coldONS/ASCO 2025 (text, p. 390); ESMO-EONS 2012 (Fig. 1, p. vii170)
Details by guideline
Risk class in extravasation
- ONS/ASCO 2025VesicantAlkylating agents, antitumor antibiotic (DNA-binding)Table 1, p. 385
- ESMO-EONS 2012VesicantVesicants › DNA-binding compounds › Others (antibiotics)Table 1, p. vii167
- JSCN/JSMO/JASPO 2024VesicantTable 2
Compress
- ONS/ASCO 2025Cold compressStrength/level: Conditional; very lowAlkylating agents per ONS/ASCO Table 1; oxaliplatin excluded because the same guideline indicates a warm compressalkylating agents, anthracyclines, and antimetabolitestext, p. 390
- ESMO-EONS 2012Cold compress"Localize and neutralize"Anthracyclines; Antibiotics (Mitomycin / Dactinomycin); Alkylating agentsFigure 1, p. vii170
Brand names (ANVISA, Brazil) · DCB (Brazil)
DCB (Brazil)dactinomicina (nº 2660)